Virus population dynamics, genetic diversity and evolution |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Vaccine to Prevent HIV Infection in Pregnancy and Newborns |
United States |
HIV/AIDS, Drug and Diagnostics Development, Newborn and Infant Health |
|
|
Testing novel adjuvants to enhance mucosal immunity elicited by inactivated poliovirus vaccine (IPV) |
United States |
Drug and Diagnostics Development, Immunology |
|
|
Subcontract Work in Association with LLNL LDRD Project: COMP-08ERD036 |
United States |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Selective AAK1 and GAK inhibitors for combating Dengue and other emerging viral infections |
United States |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Immunology |
|
|
RNAi as an Intercellular Antiviral Defense Mechanism |
United States |
Infectious Disease, Genetics |
|
|
RNA Protein Interactions in Poliovirus Replication |
United States |
Risk Reduction and Prevention |
|
|
Replication, Pathogenesis and Evolution of RNA Viruses, Including Dengue |
Argentina |
Infectious Disease, Neglected Tropical Diseases (NTDs) |
|
|
Replication fidelity mutants as attenuated poliovirus seeds for IPV production |
United States |
Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Recombinant Picornaviruses as AIDS Vaccines |
United States |
HIV/AIDS |
|
|
RAPID: Ebola virus population structure, genetic diversity and evolution |
United States |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Quasispecies and drug resistance |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Protein homeostasis mechanisms underlying enterovirus replication and evolution |
United States |
Genetics |
|
|
Mechansims of poliovirus replication |
United States |
Infectious Disease, Noncommunicable and/or Chronic Disease, Genetics |
|
|
Mechanism of enterovirus replication |
United States |
Drug and Diagnostics Development |
|
|
Linking Virus Population Genetic Structure to Infectivity and Adaptation |
United States |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Leveraging mosquito antiviral immunity to detect viral infections: Towards a scalable field-based approach for predicting arbovirus epidemics |
Mexico |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
INTERCEPT: Interfering and Co-evolving Prevention and Therapy |
United States |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Insect adaptive immunity |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Genetic Diversity as a Determinant of Viral Pathogenesis and Attenuation |
United States |
Infectious Disease, Genetics, Risk Reduction and Prevention |
|
|
Genetic Diversity as a Determinant of Viral Adaptation and Pathogenesis |
United States |
Infectious Disease, Immunology |
|
|
EV71 intra-host evolution, attenuation and vaccine development |
United States |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Cap Independent Translation of Dengue Virus |
United States |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
BSL3 upgrading for Live-attenuated poliovirus testing |
United States |
Infectious Disease, Immunology |
|
|
A Collaborative Approach to the Design of a Genetically-Stable Oral Polio Vaccine (OPV-2) |
United States |
Infectious Disease, Drug and Diagnostics Development |
|
|
2013 NIH Workshop on Protein Homeostasis and Viral Infection |
United States |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|